Interim analysis of anti-cancer vaccine, BiovaxID, to be conducted

Tampa, FL--June 13, 2007 -- Biovest International, Inc. (OTCBB: BVTI), a majority owned subsidiary of Accentia Biopharmaceuticals, Inc. (NASDAQ:ABPI) announces a milestone in its effort to gain accelerated conditional approval for BiovaxID. The independent Data Monitoring Committee (DMC) has requested an interim analysis of all primary and secondary endpoints. The DMC is the independent committee that is responsible for safety and efficacy reviews of the BiovaxID Phase 3 Clinical Trial. Further, the DMC has requested data lock to occur in September 2007 to facilitate this interim analysis.

Additionally, the DMC has informed the Company that, after its review of unblinded data for the BiovaxID Phase 3 Clinical Trial, there are no identifiable safety concerns related to this therapy. The company believes that BiovaxIDs strong safety record will be supportive of its planned application for accelerated conditional approval of BiovaxID.

BiovaxID is an anti-cancer vaccine that is in pivotal Phase 3 Clinical Trial for the indication of non-Hodgkins lymphoma (NHL). BiovaxID is a personalized, patient specific vaccine designed to stimulate the patients own immune system to recognize and destroy cancerous B-cells that may remain in the body or may arise after the patient has been treated with chemotherapy. Unlike many other approaches to treating NHL, BiovaxID is designed to kill only cancerous B-cells. The BiovaxID Phase 3 clinical trial is being conducted at fourteen oncology centers within the United States and nineteen centers in Russia.

The Chairman of the DMC, Dr. Gerry Messerschmidt, MD, FACP, stated, There are no identifiable safety concerns in the current BiovaxID Phase 3 pivotal Clinical Trial at this time in our data review. To facilitate Biovests regulatory agency discussions and petitions based on its announced decision to seek accelerated conditional approval of BiovaxID, the DMC has requested that the database be fully updated and a

Contact: Adam Holdsworth
The Investor Relations Group

Page: 1 2 3

Related biology news :

1. Interim Aranesp data suggest major response in anemic patients with MDS
2. Interim long-term follow-up data show AMG 531 increases platelets in patients with ITP
3. Interim data suggest major response with Aranesp(R) in anemic patients with MDS
4. AAAS analysis finds Congress would add billions to FY 2008 R&D investment
5. Genetic analysis finds greater threat in frog-killing fungus
6. Genomic analysis uncovers new targets for HIV vaccine
7. Manchester University helps with pharaoh DNA analysis
8. UN issues analysis of global investors sustainable energy gold rush
9. New NIST reference material for peptide analysis
10. New system for soil analysis
11. DNA analysis suggests under-reported kills of threatened whales

Post Your Comments:

(Date:4/1/2020)... ... 2020 , ... eMazzanti Technologies, an award-winning NYC technology consultant, ... announced Align2020 conference will be conducted virtually. , Align2020 is an innovative ... face current cyber security, compliance and collaboration challenges. , The virtual event is ...
(Date:4/1/2020)... ... March 31, 2020 , ... Flagship ... PMP, will join its executive team as Vice President Clinical Diagnostics. Geoff brings ... In his new role, Geoff will lead the creation and implementation of diagnostic ...
(Date:4/1/2020)... ... April 01, 2020 , ... The International ... Duliere as a European Regulatory Advisor. Effective 1 April 2020, Duliere takes on ... design for biotechnology, oral solid dosage (OSD), and sterile manufacturing. , “Jean-François brings ...
Breaking Biology News(10 mins):
(Date:4/1/2020)... , ... March 30, 2020 , ... ... its latest product, ArmourGuard® RTU, an EPA-approved spray-on antimicrobial solution. As a first-of-its-kind ... solution that provides continual antimicrobial activity against microorganisms for up to 90 days. ...
(Date:4/1/2020)... ... March 30, 2020 , ... A ... Immune Diagnostics (RID), formed earlier this year to bring telehealth to various government ... tests for COVID-19. Company officials are currently?awaiting an Emergency Use Authorization (EUA) waiver ...
(Date:4/1/2020)... ... March 31, 2020 , ... ... has developed a method using its revolutionary NEXTGENPCR endpoint thermocycler and consumables ... smaller reaction volumes, increased samples per run, and standard, affordable laboratory equipment, ...
(Date:4/1/2020)... JOLLA, Calif. (PRWEB) , ... March 31, 2020 , ... ... Jolla Institute for Immunology (LJI), announced today that they will use Carterra’s proprietary LSA™ ... move therapeutic candidates to the clinic as early as this summer. , La ...
Breaking Biology Technology:
Cached News: